MONTREAL, June 07, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Pan American (ex-US) specialty pharmaceutical company, today announced that Amal Khouri, Chief Commercial Officer, will be presenting at BIO’s 2022 International Convention on Tuesday, June 14, 2022 at 2:45 p.m. Pacific time.
Knight’s business development team will also participate in BIO’s One-on-One Partnering™, which facilitates meetings with senior biotech executives, business development executives and investors from major companies around the world.
The annual BIO International Convention, hosted by the Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders. The four-day in-person event includes networking, programming and partnership opportunities.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., based in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing pharmaceutical distribution rights for the Canadian and Latin American markets. Knight’s Latin American subsidiaries operate as United Medical, Biotoscana Farma and Laboratorio LKM. The shares of Knight Therapeutics inc. trade on the TSX under the symbol “GUD”. For more information about Knight Therapeutics Inc., visit its website at www.gud-knight.com or www.sedar.com.
Forward-Looking Statements for Knight Therapeutics Inc.
This document may contain forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such forward-looking statements. Knight Therapeutics Inc. considers that the assumptions on which these forward-looking statements are based are deemed reasonable as of the date they are made, but it warns the reader that these assumptions about future events, many of which are beyond the control of Therapeutics Knight inc. and its affiliates, may prove to be incorrect. Factors and risks that could cause actual results to differ materially from anticipated results are discussed in Knight Therapeutics Inc.’s Annual Report. and in Knight Therapeutics Inc.’s Annual Information Form. for the year ended December 31, 2021 filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statement, whether in response to new information or future events, except as required by law.
Information for investors:
